J.P. Morgan said it believes Structure has some advantages over other companies trying to enter the oral GLP-1 market, ...

GLP-1 agonist drugs like Novo Nordisk's semaglutide and Eli Lilly's tirzepatide are set to become all-time best-selling drugs. Structure Therapeutics has entered the race with an oral GLP-1 ...

Covering GLP-1 drugs under company health plans brings significant financial implications. These medications come with a ...

The current state of weight-loss treatments is about to shift with the forthcoming availability of GLP-1 drugs in the ...

Why fork over thousands of dollars a month for prescription weight loss jabs when store-bought supplements claim to have the ...

Among the companies racing to develop oral weight-loss drugs, Structure Therapeutics Inc. (GPCR) is another strong contender, in the analysts' view. The company's oral GLP-1 drug, GSBR-1290 ...

Viking Therapeutics' VK2735, a dual GLP-1/GIP receptor agonist ... While Roche's and Structure's oral product candidates might gain strength as potential competitors if the companies accelerate ...

In metabolic dysfunction-associated steatotic liver disease, a retrospective analysis shows that patients on GLP-1 receptor ...

We think it's possible that 16 new obesity drugs could launch by 2029, with roughly $70 billion of the GLP-1 market coming from ... targets including Viking and Structure will likely take market ...

Animal testing of combination DehydraTECH-CBD with DehydraTECH-GLP-1 drugs is ongoing and in the final phases ... co-formulation is required rather than co-administration. The structure of liraglutide ...

Ken Cohen, MD, of Optum Care, advocates for glucagon-like peptide 1 (GLP-1) tiering for patients with diabetes based on comorbidities, like body mass index (BMI) and cardiovascular disease (CVD).